Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | SLC9A1 | P19634 | 4/20 | 0.59 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.59 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1560207 | 0.91 | NPC1 (0.61) | RAB9ANPC1MAPTSLC9A1GRM2 | |
| SCHEMBL14953587 | 0.84 | SLC9A1 (0.63) | RAB9ANPC1MAPTSLC9A1GRM2 | |
| SCHEMBL3403852 | 0.84 | SLC9A1 (0.63) | RAB9ANPC1MAPTSLC9A1GRM2 | |
| SCHEMBL5421073 | 0.81 | SLC9A1 (0.63) | RAB9ANPC1MAPTSLC9A1GRM2 | |
| SCHEMBL1560258 | 0.79 | CYP1A2 (0.49) | RAB9ANPC1MAPTSLC9A1GRM2 | |
| SCHEMBL3428426 | 0.79 | NPC1 (1.00) | RAB9ANPC1MAPTSLC9A1GRM2 | |
| SCHEMBL2494163 | 0.79 | RPS6KA3 (0.77) | RAB9ANPC1MAPTSLC9A1GRM2 | |
| SCHEMBL5434963 | 0.79 | SLC9A1 (0.65) | RAB9ANPC1MAPTSLC9A1GRM2 | |
| SCHEMBL5427180 | 0.78 | SLC9A1 (0.66) | RAB9ANPC1MAPTSLC9A1GRM2 | |
| SCHEMBL14953637 | 0.78 | SLC9A1 (0.66) | RAB9ANPC1MAPTSLC9A1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003785-B2 | Halo-substituted pyrimidodiazepines | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2303889-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20090318408-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
| WO-2009153197-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318408-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES | PLK1, CCNI, CDK1 | RAB9A 2627/4885NPC1 1638/4885MAPT 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.